CYTK Cytokinetics, Incorporated
Healthcare$76.29-0.84%ClosedMarket Cap: $9.49B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-11.47
P/S
90.48
EV/EBITDA
-14.06
DCF Value
$-59.58
FCF Yield
-5.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.3%
Operating Margin
-605.1%
Net Margin
-784.0%
ROE
139.7%
ROA
-65.1%
ROIC
-56.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $19.4M | 87.6% | $-183.6M | $-206.0M | $— | — |
| Q4 null | $17.8M | 83.9% | $-178.4M | $-183.0M | $— | — |
| FY null | $88.0M | 88.5% | $-612.3M | $-785.0M | $— | — |
| Q3 null | $1.9M | -38.4% | $-166.8M | $-306.2M | $— | — |
| Q2 null | $66.8M | 96.6% | $-111.5M | $-134.4M | $— | — |
| Q1 null | $1.6M | -6223.1% | $-155.6M | $-161.4M | $— | — |
| Q4 null | $16.9M | -453.1% | $-139.0M | $-150.0M | $— | — |
| FY null | $18.5M | -1737.2% | $-536.2M | $-589.5M | $— | — |
| Q3 null | $463.0K | -18174.7% | $-140.8M | $-160.5M | $— | — |
| Q2 null | $249.0K | -31866.7% | $-130.2M | $-143.3M | $— | — |
| Q1 null | $835.0K | -9668.9% | $-126.2M | $-135.6M | $— | — |
| Q4 2023 | $1.7M | -4982.3% | $-127.4M | $-136.9M | $-1.38 | — |